<DOC>
	<DOCNO>NCT00930865</DOCNO>
	<brief_summary>To assess potential pharmacokinetic ( PK ) interaction bumetanide dapagliflozin follow multiple dos 1 mg bumetanide 10 mg dapagliflozin healthy subject</brief_summary>
	<brief_title>Study Evaluate Potential Pharmacokinetic Interaction Pharmacodynamic Effects Renal Parameters Bumetanide ( 1mg ) Dapagliflozin ( 10 mg ) When Co-administered Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Bumetanide</mesh_term>
	<criteria>Healthy subject determine clinically significant deviation normal medical history , physical examination , ECGs , clinical laboratory determination Body Mass Index ( BMI ) 18 32 kg/m² , inclusive . BMI = weight ( kg ) / [ height ( ) ] ² Women childbearing potential ( WOCBP ) must use adequate method contraception avoid pregnancy throughout study manner risk pregnancy minimize men , age 18 45 WOCBP unwilling unable use acceptable method avoid pregnancy entire study period Any significant acute chronic medical illness Current recent ( within 3 month ) gastrointestinal disease Current smoker recent ( within 1 month ) history regular tobacco use Evidence organ dysfunction clinically significant deviation normal physical examination , vital sign , ECG clinical laboratory determination beyond consistent target population Abnormal urinalysis screen Glucosuria screen Abnormal liver function test ( ALT , AST total bilirubin &gt; 10 % ULN ) Presence edema physical exam History diabetes mellitus History heart failure History renal insufficiency History chronic recurrent UTI ( define 3 occurrence per year ) UTI past 3 month Positive urine screen drug abuse either screen dose Positive blood screen hepatitis C antibody , hepatitis B surface antigen , HIV1 , 2 antibody History allergy SGLT2 inhibitor , bumetanide ( related compound ) History significant drug allergy ( anaphylaxis hepatotoxicity ) Prior exposure dapagliflozin within 3 month Day 1 Exposure investigational drug placebo within 4 week Day 1 Use prescription drug within 4 week overthecounter acid controller within 2 week prior study drug administration Use drug , include overthecounter medication within 1 week herbal preparation , within 2 week prior study drug administration Use oral , injectable implantable hormonal contraceptive agent within 3 month study drug administration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>